全文获取类型
收费全文 | 1269677篇 |
免费 | 99753篇 |
国内免费 | 1980篇 |
专业分类
耳鼻咽喉 | 18405篇 |
儿科学 | 44239篇 |
妇产科学 | 34992篇 |
基础医学 | 180908篇 |
口腔科学 | 33557篇 |
临床医学 | 110604篇 |
内科学 | 256099篇 |
皮肤病学 | 28004篇 |
神经病学 | 99703篇 |
特种医学 | 51164篇 |
外国民族医学 | 660篇 |
外科学 | 195718篇 |
综合类 | 27020篇 |
现状与发展 | 1篇 |
一般理论 | 377篇 |
预防医学 | 95142篇 |
眼科学 | 27794篇 |
药学 | 94512篇 |
2篇 | |
中国医学 | 2336篇 |
肿瘤学 | 70173篇 |
出版年
2018年 | 13123篇 |
2017年 | 9961篇 |
2016年 | 10897篇 |
2015年 | 12370篇 |
2014年 | 17162篇 |
2013年 | 26209篇 |
2012年 | 36016篇 |
2011年 | 38050篇 |
2010年 | 22798篇 |
2009年 | 21806篇 |
2008年 | 36634篇 |
2007年 | 39244篇 |
2006年 | 39498篇 |
2005年 | 38437篇 |
2004年 | 37581篇 |
2003年 | 36342篇 |
2002年 | 35704篇 |
2001年 | 63888篇 |
2000年 | 66318篇 |
1999年 | 56060篇 |
1998年 | 14354篇 |
1997年 | 12987篇 |
1996年 | 13405篇 |
1995年 | 13383篇 |
1994年 | 12718篇 |
1993年 | 11725篇 |
1992年 | 44500篇 |
1991年 | 43453篇 |
1990年 | 42202篇 |
1989年 | 40090篇 |
1988年 | 36864篇 |
1987年 | 36218篇 |
1986年 | 33591篇 |
1985年 | 32263篇 |
1984年 | 24118篇 |
1983年 | 20215篇 |
1982年 | 11682篇 |
1981年 | 10638篇 |
1980年 | 9459篇 |
1979年 | 21299篇 |
1978年 | 14785篇 |
1977年 | 12489篇 |
1976年 | 11667篇 |
1975年 | 12600篇 |
1974年 | 14643篇 |
1973年 | 14101篇 |
1972年 | 12938篇 |
1971年 | 11714篇 |
1970年 | 11039篇 |
1969年 | 10012篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
Bielik Peter Bonczek Ondřej Krejčí Přemysl Zeman Tomáš Izakovičová-Hollá Lydie Šoukalová Jana Vaněk Jiří Vojtěšek Bořivoj Lochman Jan Balcar Vladimir J. Šerý Omar 《Clinical oral investigations》2022,26(12):7045-7055
Clinical Oral Investigations - The aim of this study was the analysis of WNT10A variants in seven families of probands with various forms of tooth agenesis and self-reported family history of... 相似文献
42.
43.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
44.
Bobo H. P. Lau Ting-Kin Ng Yat-Lui Fung Tai-Chung Lam Tsz-Him So 《Journal of psychosocial oncology》2020,38(4):389-405
AbstractPurposes/objectives: This paper reports the comparative efficacies of integrative body-mind-spirit intervention (I-BMS) and cognitive behavioral therapy (CBT) in patient-caregiver parallel groups for Chinese patients with lung cancer.Design: Randomized controlled trial (RCT).Methods: One hundred and fifty-seven patient-caregiver dyads with no marked functional impairment were randomized into one of the two interventions with eight weekly patient-caregiver parallel groups. Assessments were conducted at baseline, within one, eight- and sixteen-weeks post-intervention. Effects of treatment group across time were analyzed by multilevel modeling.Findings: CBT led to greater reduction in emotional vulnerability than I-BMS. I-BMS resulted in greater increase in overall QoL and spiritual self-care, and more reduction in depression than CBT. Patients in both interventions experienced improvement in physical, emotional and spiritual, except social, domains of QoL.Conclusion: I-BMS was more efficacious for diverse domains of QoL, and CBT was more effective for emotional well-being, despite the relatively small between-group effect sizes.Implications for psychosocial providers/policy: (1) With the expanding repertoire of psychosocial interventions for families facing lung cancer, it has become imperative to investigate the comparative efficacies of empirically supported and culturally adapted interventions. (2) Our findings show that I-BMS was more effective for diverse domains of QoL, while CBT was more efficacious with emotional well-being, although both interventions led to significant improvements in physical, emotional and spiritual domains of patient QoL. (3) Patient-caregiver parallel groups have been shown to be effective for enhancing QoL of Chinese lung cancer patients. (4) Care professionals are encouraged to dispense interventions based on the idiosyncratic needs and preferences of the patients to maximize the treatment effects. 相似文献
45.
46.
47.
M.S. Iqbal G. Vashisht R. McMenemin P. Atherton F. McDonald T. Simmons A. Bradshaw J. Kovarik H. Turnbull L. Dodd P. Mulvenna A. Greystoke 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):e1-e10
Aims
Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.Materials and methods
One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.Results
In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.Conclusion
Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial. 相似文献48.
49.
Monika Kasper-Sonnenberg Holger M. Koch Petra Apel Maria Rüther Claudia Pälmke Thomas Brüning Marike Kolossa-Gehring 《International journal of hygiene and environmental health》2019,222(8):1084-1092
DINCH (cyclohexane-1,2-dicarboxylic acid-diisononyl ester) is a phthalate plasticizer substitute introduced into the market in 2002. It is increasingly used especially in the production of toys, food contact materials and medical devices. In this measurement campaign on 24-h urine samples of young adults (20–29 years) from the German Environmental Specimen Bank (ESB) collected in 2010, 2011, 2013, 2015 and 2017 (in total 300 samples, 60 samples/year) we analyzed three specific, oxidized DINCH metabolites (OH-MINCH: cyclohexane-1,2-dicarboxylic acid-mono(hydroxy-isononyl) ester; cx-MINCH: cyclohexane-1,2-dicarboxylic acid-mono(carboxy-isooctyl) ester, oxo-MINCH: cyclohexane-1,2-dicarboxylic acid-mono(oxo-isononyl) ester). We merged these data with earlier data of the ESB from the years 1999–2012 and are now able to report levels and time trends of internal DINCH exposure from 1999 to 2017.After first detections of the major oxidized DINCH metabolite OH-MINCH in 2006 (6.7%) detection rates rapidly increased to 43.3% in 2009, 80% in 2010 and 98.3% in 2011 and 2012. From the year 2013 on we could detect OH-MINCH in every urine sample analyzed. The median concentrations of OH-MINCH rapidly increased from 0.15 μg/L in 2010 to twice the concentration in 2011 (0.31 μg/L) with further increases in 2013 (0.37 μg/L), 2015 (0.59 μg/L) and 2017 (0.70 μg/L). Similar increases, albeit at lower detection rates and concentration levels, could be observed for cx-MINCH and oxo-MINCH. All metabolites strongly correlate with each other.For the ESB study population, DINCH exposures are still far below health based guidance values such as the German Human Biomonitoring Value (HBM-I; 4,500 μg/L for the sum of OH-MINCH and cx-MINCH) or the tolerable daily intake (TDI) of EFSA (1 mg/kg bw/d). The median daily DINCH intake (DI) calculated for 2017 was 0.23 μg/kg bw/d, thus 4,310-times lower than the TDI. The maximum DI calculated for one individual in 2012 (42.60 μg/kg bw/d) was a factor of more than 20 below the TDI.The ongoing increase in DINCH exposure needs to be closely monitored in the future, including populations with potentially higher exposures such as children. This close monitoring will enable timely exposure and risk reduction measures if exposures reached critical levels, or if new toxicological data lead to lower health based guidance values. DINCH belongs to the European Human Biomonitoring Initiative (HBM4EU) priority substances for which policy relevant questions still have to be answered. 相似文献
50.
Imre W.K. Kouw Bart B.L. Groen Joey S.J. Smeets Irene Fleur Kramer Janneau M.X. van Kranenburg Rachél Nilwik Jan A.P. Geurts René H.M. ten Broeke Martijn Poeze Luc J.C. van Loon Lex B. Verdijk 《Journal of the American Medical Directors Association》2019,20(1):35-42